逆转激素抵抗：我们找到金钥匙了吗？ - Suppr

Reversing hormone resistance: have we found the golden key?

作者信息

Rugo Hope S, Keck Sara

出版信息

J Clin Oncol. 2012 Aug 1;30(22):2707-9. doi: 10.1200/JCO.2012.42.1271. Epub 2012 Jul 2.

DOI:10.1200/JCO.2012.42.1271

PMID:22753913

Abstract

摘要

相似文献

Reversing hormone resistance: have we found the golden key?

J Clin Oncol. 2012 Aug 1;30(22):2707-9. doi: 10.1200/JCO.2012.42.1271. Epub 2012 Jul 2.

Appropriate design of prospective studies.

J Clin Oncol. 2013 Feb 1;31(4):510-1. doi: 10.1200/JCO.2012.46.0980. Epub 2012 Dec 26.

Reply to J.-H. Choi et al.

J Clin Oncol. 2013 Feb 1;31(4):511. doi: 10.1200/JCO.2012.46.7399.

Postmenopausal hormone receptor-positive advanced breast cancer.

Oncology (Williston Park). 2013 Jun;27(6):571-2, 574, 576 passim.

A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.

Oncology (Williston Park). 2018 Jun;32(6):298-302.

Hints of future progress for HER-2 breast cancer.

J Natl Cancer Inst. 2011 Apr 6;103(7):535-7. doi: 10.1093/jnci/djr122. Epub 2011 Mar 23.

[Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer].

Nihon Rinsho. 2007 Jun 28;65 Suppl 6:396-401.

Moving away from the "one shoe fits all" strategy: the key to future progress in chemotherapy.

J Clin Oncol. 2005 Mar 10;23(8):1611-3. doi: 10.1200/JCO.2005.01.007.

Dasatinib-letrozole gets split verdict.

Cancer Discov. 2014 Feb;4(2):138-9. doi: 10.1158/2159-8290.CD-NB2013-181. Epub 2014 Jan 2.

The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer.

Nat Clin Pract Oncol. 2005 Dec;2(12):596-7. doi: 10.1038/ncponc0360.

引用本文的文献

Overview of the therapeutic strategies for ER positive breast cancer.

Biochem Pharmacol. 2023 Jun;212:115552. doi: 10.1016/j.bcp.2023.115552. Epub 2023 Apr 15.

Clinical-Pathologic Analysis of Breast Cancer With PIK3CA Mutations in Chinese Women.

Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820950832. doi: 10.1177/1533033820950832.

Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer.

JAMA Netw Open. 2020 Jul 1;3(7):e209486. doi: 10.1001/jamanetworkopen.2020.9486.

Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer.

Oncologist. 2018 Jun;23(6):660-669. doi: 10.1634/theoncologist.2017-0343. Epub 2018 Feb 27.

Genetic variants in the mTOR pathway and interaction with body size and weight gain on breast cancer risk in African-American and European American women.

Cancer Causes Control. 2016 Aug;27(8):965-76. doi: 10.1007/s10552-016-0774-x. Epub 2016 Jun 17.

Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer.

Oncologist. 2016 Aug;21(8):922-30. doi: 10.1634/theoncologist.2015-0366. Epub 2016 Jun 2.

Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.

Virchows Arch. 2016 Jul;469(1):35-43. doi: 10.1007/s00428-016-1938-5. Epub 2016 Apr 8.

Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2.

Neoplasia. 2015 Mar;17(3):279-88. doi: 10.1016/j.neo.2015.01.005.

Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer.

Curr Oncol. 2015 Feb;22(1):33-48. doi: 10.3747/co.22.2393.

Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.

Int J Clin Exp Med. 2014 Oct 15;7(10):3333-43. eCollection 2014.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Reversing hormone resistance: have we found the golden key?

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Reversing hormone resistance: have we found the golden key?

作者信息

出版信息

相似文献

引用本文的文献